ABHD14B Inhibitors

ABHD14B inhibitors are chemicals that interfere with the activity of the ABHD14B enzyme. Since specific inhibitors for ABHD14B are not well-documented, the compounds listed above are general serine hydrolase inhibitors that can potentially inhibit ABHD14B by targeting its active site or altering its conformation. These inhibitors are designed to interact with the serine residue that is essential for the catalytic activity of this class of enzymes. For example, MAFP and PF-3845 inhibit serine hydrolases by covalently binding to the serine residue in the active site, preventing the enzyme from processing its substrates. This mechanism is a common approach for inhibiting serine hydrolases and could be effective against ABHD14B.

Other compounds, such as WWL70 and URB602, may inhibit ABHD14B through an allosteric mechanism, inducing a conformational change that reduces enzymatic activity. Compounds like orlistat, THL, and palmostatin B act by forming a covalent bond with the serine residue at the hydrolase's active site, inactivating the enzyme and blocking substrate access. JZL184, JZL195, KT185, and KT203 target specific serine hydrolases and could potentially inhibit ABHD14B by similar mechanisms. The class of ABHD14B inhibitors represents a diverse array of chemical structures and mechanisms designed to interfere with the enzyme's function. While some compounds directly target the active site serine residue, others achieve inhibition through allosteric modulation or covalent modification of essential residues.